Boehringer Ingelheim entered a licensing agreement potentially worth more than 1.1 billion euros ($1.3 billion) to jointly develop OSE Immunotherapeutics' experimental checkpoint inhibitor OSE-172 for the treatment of advanced solid tumours, the companies announced. Under the deal, Boehringer Ingelheim will make an upfront payment of 15 million euros ($18.4 million) to OSE Immunotherapeutics, with the latter eligible to receive short-term milestones of up to 15 million euros upon initiation of a Phase I study.
The drugmakers noted that OSE-172 prevents the ligand CD47 from binding to and triggering the cellular inhibitory effects of SIRP-alpha, with the monoclonal antibody having the potential to enhance antitumour immunity by improving T-cell activity. Jonathon Sedgwick, global head of cancer immunology and immune modulation research at Boehringer Ingelheim, noted that one of the company's "key area[s] of focus is the identification of drugs that target myeloid cell immune regulatory receptors of which SIRP-alpha is a leading example."
As part of the agreement, under which Boehringer Ingelheim gains global rights to develop, register and commercialise OSE-172, OSE Immunotherapeutics stands to receive more than 1.1 billion euros linked to development, commercialisation and sales milestones, plus royalties on worldwide net sales. OSE-172 is currently in late-stage preclinical development.
To read more Top Story articles, click here.